Business Context and Reporting Period
This Form 8-K Current Report was filed by ReShape Lifesciences Inc. (RSLS) on July 16, 2021. The filing details a material definitive agreement entered into on the same date with existing institutional investors regarding the exchange of outstanding warrants. The company is an emerging growth company incorporated in Delaware with principal executive offices in San Clemente, CA.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margin, or debt metrics. The primary financial impact relates to equity capitalization:
- Common Stock Issued: 504,861 shares issued to investors in exchange for warrants.
- Valuation Basis: Shares were calculated using a price of $4.038, representing 95% of the closing market price on July 16, 2021.
- New Warrants Issued: Warrants to purchase up to 400,000 shares of common stock.
- Warrant Terms: Exercise price of $4.038 with a five-year term.
- Total Outstanding Shares: 15,842,185 shares following the issuance.
Material Changes Versus Prior Period
The filing reports a specific transactional change rather than a period-over-period financial comparison. The material change involves the conversion of "Exchange Warrants" (originally issued prior to the merger of Obalon Therapeutics, Inc. and ReShape Lifesciences Inc.) into common stock and new warrants. This exchange was executed in lieu of a cash payment (Black Scholes Payment) that investors were entitled to receive following the merger, which constituted a fundamental transaction under the original warrant terms.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of general business risks. Specific contingencies and unusual items noted include:
- Unregistered Sale: The new warrants and associated shares were offered in a private placement to accredited investors pursuant to Section 3(a)(9) of the Securities Act and have not been registered with the SEC.
- Resale Restrictions: These securities may not be offered or sold in the United States absent registration or an applicable exemption.
- Legal Basis: The transaction relied on the Black Scholes valuation model to determine the value of the exchanged warrants.
Investor Verification Checklist
- Verify the total number of outstanding shares (15,842,185) and the dilution impact of the 504,861 newly issued shares.
- Confirm the terms of the new warrants (400,000 shares, $4.038 exercise price, 5-year term) via Exhibit 4.1.
- Review the full text of the Exchange Agreement (Exhibit 10.1) for any additional covenants or conditions not summarized in the 8-K.
- Assess the impact of the unregistered status of the new warrants on future liquidity and potential resale restrictions.